Study of SHR-1139 for plaque psoriasis
Part of Skin clinical trials.
This study tests an investigational drug called SHR-1139 for people with moderate-to-severe plaque psoriasis who have not responded well to previous biologic treatments. The goal is to see if it can reduce psoriasis symptoms safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have had plaque psoriasis for at least 6 months.
- You must have tried at least one biologic medicine (e.g., Humira, Enbrel, Stelara) at a standard dose and it didn't work well enough.
- You cannot have other types of psoriasis or active infections like tuberculosis or hepatitis.
- You cannot have taken certain psoriasis treatments recently (like topical creams within 2 weeks, or biologics within a certain period).
- You must be generally healthy aside from psoriasis, with no recent heart, liver, or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This trial tests a new study drug (ZP9830) to see if it is safe and works well for people with plaque psoriasis. You would receive the treatment for 8 weeks, and the study will check how your skin responds.
This study tests an oral medication (HSK47388) as a treatment for moderate-to-severe plaque psoriasis, the most common type. It may help reduce symptoms like red, scaly patches and improve quality of life.
This trial tests an oral medication called ICP-332 versus a placebo (a pill with no active drug) for people with moderate to severe plaque psoriasis. The goal is to see if ICP-332 can improve skin symptoms and be safe.
This study tests how well a biologic medication works and what happens when it is stopped in adults with moderate-to-severe plaque psoriasis. It may help you find a treatment that controls your symptoms and also informs you about managing your condition.
This study tests a new injection called SHR-1139 for people with moderate-to-severe plaque psoriasis. The goal is to see if it can safely improve your skin condition.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.